Inhibition of COX-2 cannot be suggested for colorectal cancer prevention in general, because the use of selective as well as non-selective COX-2 inhibitors bears a strong risk of thrombotic cardiovascular events in individuals with a high risk for cardiovascular disease (for review, see [32]). The gene discussed is PTGS2; the disease is cardiovascular disorder.